IRMA-International.org: Creator of Knowledge
Information Resources Management Association
Advancing the Concepts & Practices of Information Resources Management in Modern Organizations

Aß Monomer, Oligomer and Fibril in Alzheimer’s Disease

Aß Monomer, Oligomer and Fibril in Alzheimer’s Disease
View Sample PDF
Author(s): Hiroshi Mori (Osaka City University Medical School, Japan)
Copyright: 2013
Pages: 7
Source title: Bioinformatics: Concepts, Methodologies, Tools, and Applications
Source Author(s)/Editor(s): Information Resources Management Association (USA)
DOI: 10.4018/978-1-4666-3604-0.ch080

Purchase

View Aß Monomer, Oligomer and Fibril in Alzheimer’s Disease on the publisher's website for pricing and purchasing information.

Abstract

Alzheimer’s disease (AD), the most prevalent disease of aged people, is a progressive neurodegenerative disorder with dementia. Amyloid-ß (also known as ß-protein and referred to here as Aß) is a well-established, seminal peptide in AD that is produced from the amyloid precursor protein (APP) by consecutive digestion with the ß secretase of BACE (beta-site amyloid cleaving enzyme) and gamma secretase of the presenilin complex. Abnormal cerebral accumulation of Abeta in the form of insoluble fibrils in senile plaques and cerebral amyloid angiopathy (CAA) is a neuropathological hallmark of AD. In contrast to insoluble fibrillary Aß, a soluble oligomeric complex, ADDL, consists of low-n oligomers of Aß, such as Aß*56. Despite their different names, it is currently proposed that oligomeric Aß is directly involved in synaptic toxicity and cognitive dysfunction in the early stages of AD. This chapter identifies a novel APP mutation (E693delta; referred to as the Osaka mutation) in a pedigree with probable AD, resulting in a variant Aß lacking glutamate at position 22. Based on theoretical predictions and in vitro studies on synthetic mutant Aß peptides, the mutated Aß peptide showed a unique and enhanced oligomerization activity without fibrillization. This was further confirmed by PiB-PET analysis on the proband patient. Collectively, the chapter concludes that the Osaka mutation is the first human evidence for the hypothesis that oligomeric Aß is involved in AD.

Related Content

Linkon Chowdhury, Md Sarwar Kamal, Shamim H. Ripon, Sazia Parvin, Omar Khadeer Hussain, Amira Ashour, Bristy Roy Chowdhury. © 2024. 20 pages.
Mousomi Roy. © 2024. 21 pages.
Nassima Dif, Zakaria Elberrichi. © 2024. 20 pages.
Pyingkodi Maran, Shanthi S., Thenmozhi K., Hemalatha D., Nanthini K.. © 2024. 16 pages.
Mohamed Nadjib Boufenara, Mahmoud Boufaida, Mohamed Lamine Berkane. © 2024. 16 pages.
Meroua Daoudi, Souham Meshoul, Samia Boucherkha. © 2024. 25 pages.
Zhongyu Lu, Qiang Xu, Murad Al-Rajab, Lamogha Chiazor. © 2024. 56 pages.
Body Bottom